Open Access Open Access  Restricted Access Subscription or Fee Access

The use of Genetics and Proteomics in the Finding of Therapeutic Targets

Ankita Sharma


Gene medicine is overcoming long-standing health issues that have confounded humanity. To fully comprehend and apply gene medicine, it is vital to grasp how it works at the molecular level. Currently, various technologies may be utilized to find pharmacological targets; the two most prominent are genomic and proteomic methods. In this paper, we go over how to use genomic and proteomic approaches to find pharmacological targets in depth. These materials will help you learn and apply the two strategies for discovering new gene therapy medication targets. Drug discovery and development are critical to humanity's well-being and the pharmaceutical industry's long-term viability. Because of the Human Genome Project's completion, using chemical biology methodologies to discover therapeutic leads has become a generally acknowledged path. Chemical biology mostly solves biological problems by identifying ligands for well-defined therapeutic targets or searching for newly identified targets for pharmacologically active small compounds. It's a useful tool for figuring out how these small molecules interact with their targets, as well as their involvement in signaling, molecular recognition, and cell functions. As a result of developments in functional genomics, a growing number of new therapeutic targets have been identified and validated, leading to the discovery of multiple active small compounds through a variety of high-throughput screening activities. We highlight certain chemical biology applications in the context of drug discovery in this review.


Drug target, Genomics, Proteomics, Gene medicine, Therapeutic strategies

Full Text:



Rolland, Alain P. "From genes to gene medicines: recent advances in nonviral gene delivery." Critical Reviews™ in Therapeutic Drug Carrier Systems 15.2 (1998).

Kim, Sung Wan. "Polymeric gene delivery for diabetic treatment." Diabetes & Metabolism Journal 35.4 (2011): 317–326.

Lindsay, Mark A. "Target discovery." Nature Reviews Drug Discovery 2.10 (2003): 831–838.

Ahn, Natalie G., and Andrew HJ Wang. "Proteomics and genomics: perspectives on drug and target discovery." Current opinion in chemical biology 12.1 (2008): 1.

Ferrer-Alcón, Marcel, et al. "The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics." Toxicology letters 186.1 (2009): 45–51.

Trist, David G. "Scientific process, pharmacology and drug discovery." Current opinion in pharmacology 11.5 (2011): 528–533.

Imming, Peter, Christian Sinning, and Achim Meyer. "Drugs, their targets and the nature and number of drug targets." Nature reviews Drug discovery 5.10 (2006): 821–834.

Zhu, Yue, et al. "Application of chemical biology in target identification and drug discovery." Archives of pharmacal research 38.9 (2015): 1642–1650.

Mandel, Silvia, Orly Weinreb, and Moussa BH Youdim. "Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs." TRENDS in Pharmacological Sciences 24.4 (2003): 184–191.

Wang, Kai, et al. "Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray." Gene 229.1-2 (1999): 101–108.

DeRisi, Joseph, et al. "Use of a cDNA microarray to analyse gene expression." Nat. genet 14 (1996): 457-460.

Kapp, Ursula, et al. "Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells." The Journal of experimental medicine 189.12 (1999): 1939-1946.

Wang, Yixin, et al. "Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology." FEBS letters 445.2-3 (1999): 269-273.


  • There are currently no refbacks.